Indication: Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic L

A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene
Rearrangement (CIRB)

Sub-indication: Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic L

Drug Study

Principal Investigator: Ashok Raj, M.D.
Norton Children's Cancer Institute, affiliated with the UofL School of Medicine

Sponsor: Children's Oncology Group (COG)

Search our entire site.